Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates

Circulation Research

Volumn 87, Issue 11, 2000, Pages 1063-1068

  Kawauchi, Motohiro ^a   Suzuki, Jun Ichi ^b,e   Morishita, Ryuichi ^d   Wada, Yuko ^b   Izawa, Atsushi ^b   Tomita, Naruya ^d   Amano, Jun ^b   Kaneda, Yasufumi ^d   Ogihara, Toshio ^d   Takamoto, Shinichi ^a   Isobe, Mitsuaki ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Arteriosclerosis; Gene therapy; Heart transplantation; Primate; Transcription factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE; LIPOSOME; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CYCLE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GRAFT FAILURE; HEART TRANSPLANTATION; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIMATE; PRIORITY JOURNAL; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ENVELOPE;

EID: 0034711518     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.87.11.1063     Document Type: Article

References (42)

1. The registry of the international society for heart and lung transplantation: Sixteenth official report-1999
2. Immune mechanism of cardiac allograft vasculopathy: An update
3. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide
4. Association of cdk 2 kinase with the transcription factor E2F during S phase
5. Retinoblastoma protein switches the E2F site from positive to negative element
6. A gene strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
7. Fusigenic viral liposome for gene therapy in cardiovascular diseases
8. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer
9. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
10. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: A comparative study with captopril
11. Diagnosis of cardiac allograft rejection by the detection of circulating plasma cardiac myosin light chains
12. Inhibition of accelerated coronary atherosclerosis with short-term blockade of ICAM-1 and LFA-1 in a heterotopic murine model of cardiac transplantation
13. Expression of cell division cycle 2 kinase transcription in chronically rejected cardiac allografts of non-human primates
14. Use of the deoxyinosine-containing probe to isolate and sequence cDNA encoding the fusion (F) glycoprotein of Sendai virus (HVJ)
15. Molecular cloning of a full-length cDNA encoding the hemagglutinin-neuraminidase glycoprotein of Sendai virus
16. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allograft: A study in rat and monkey models
17. Analysis of giant polynuclear cell formation caused by HVJ virus from Ehrlich ascites tumor cells
18. Development of coronary artery disease in cardiac transplanted patients receiving immunosuppressive therapy with cyclosporine and prednisone
19. Diltiazem in the prevention of coronary artery disease in heart-transplant recipients
20. Cytoskeletal features of rat aortic cells during development: An electron microscopic, immunohistochemical, and biochemical study
21. Leukocyte adhesion to endothelium in inflammation
22. Cyclosporine A inhibits induction of DNA synthesis by PDGF and other peptide mitogens in cultured rat aortic smooth muscle cells and dermal fibroblasts
23. A cascade of model for restenosis: A special case of atherosclerosis progression
24. Regulation of smooth muscle cell growth in injured artery
25. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery
26. Cyclin A is required at two points in the human cell cycle
27. A restriction point for control of normal animal cell proliferation
28. Isolation of the human cdk2 gene that encodes the cyclin A and adenovirus E1A associated p33 kinase
29. Doxazosin inhibits retinoblastoma protein phosphorylation and G(1)→S transition in human coronary smooth muscle cells
30. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
31. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53
32. Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis
33. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury
34. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty
35. Retinoblastoma protein switches the E2F site from positive to negative element
36. Human cyclin-dependent kinase 2 is activated during S and G2 phases of the cell cycle and associates with cyclin A
37. Cloning of the Xenopus laevis cdk2 promoter and functional analysis in oocytes and during early development
38. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
39. Increased expression of DNA cointroduced with nuclear protein in adult rat liver
40. Pharmacokinetics of antisense oligodeoxyrebonucleotides (cyclin B1 and CDC2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery
41. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides
42. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer